Literature DB >> 8907571

Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases.

T Ueno1, S Tamaki, H Sugawara, S Inuzuka, T Torimura, M Sata, K Tanikawa.   

Abstract

BACKGROUND/AIMS: This study was performed to assess the significance of elevated serum tissue inhibitor of metalloproteinases-1 concentration in various liver diseases.
METHODS: Tissue inhibitor of metalloproteinases-1 levels were measured in patients with various liver diseases, and were compared with serum type III procollagen-N-peptide (P III P), type IV collagen and laminin P1 levels, as well as with the histology of liver biopsy specimens.
RESULTS: Mean tissue inhibitor of metalloproteinases-1 levels were significantly higher in subjects with acute viral hepatitis, cirrhosis, alcoholic hepatitis, and alcoholic cirrhosis than in the control group (p < 0.05). Serum tissue inhibitor of metalloproteinases-1 levels in the various liver diseases showed positive correlation with serum type IV collagen, P III P, and laminin P1 levels. Regarding the relationship between tissue inhibitor of metalloproteinases-1 and liver histology, serum tissue inhibitor of metalloproteinases-1 levels correlated with the degree of hepatic fibrosis and inflammation, such as focal necrosis and cell infiltration. Furthermore, elevated serum tissue inhibitor of metalloproteinases-1 levels were especially related to the cell infiltration, focal necrosis, portal fibrosis, and serum type IV collagen level.
CONCLUSIONS: These findings suggest that the measurement of the serum tissue inhibitor of metalloproteinases-1 level in various liver diseases may be useful to estimate the active hepatic fibrogenesis associated with the active inflammatory stage of the liver injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8907571     DOI: 10.1016/s0168-8278(96)80027-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  4 in total

1.  Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis.

Authors:  Tamara N Pereira; Meagan J Walsh; Peter J Lewindon; Grant A Ramm
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

2.  Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.

Authors:  K M Walsh; P Timms; S Campbell; R N MacSween; A J Morris
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

3.  Evidence for altered hepatic matrix degradation in genetic haemochromatosis.

Authors:  D K George; G A Ramm; L W Powell; L M Fletcher; N I Walker; L L Cowley; D H Crawford
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

4.  Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children.

Authors:  Yasser E Nassef; Mones M Abu Shady; Essam M Galal; Manal A Hamed
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.